Virani Shafique 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Sep 19, 2023
Insider Transaction Report
Form 4
Virani Shafique
Chief Corp. Dev. Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2023-09-15$2.22/sh+18,000$39,960→ 158,351 total - Sale
Class A Common Stock
2023-09-15$8.66/sh−18,000$155,880→ 140,351 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-15−18,000→ 433,469 totalExercise: $2.22Exp: 2030-03-03→ Class A Common Stock (18,000 underlying)
Holdings
- 212,507
Stock Option (Right to Buy)
Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying) - 80,450
Stock Option (Right to Buy)
Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 5,436
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying)
Footnotes (4)
- [F1]Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
- [F2]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F3]One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
- [F4]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.